A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma

Nature Communications

Volumn 6, Issue , 2015, Pages

  Goiffon, Reece J ^a   Martinez, Sara C ^a   Piwnica Worms, David ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE; POLYMER; AMMONIUM SULFATE; ANTIOXIDANT; L 012; LUMINOL; PEROXIDASE; PROTEIN BINDING;

BIOASSAY; CARDIOVASCULAR DISEASE; CONCENTRATION (COMPOSITION); ENZYME ACTIVITY; HEALTH RISK; IMMUNE RESPONSE; POLYMER;

ADULT; ARTICLE; BIOLUMINESCENCE; BROMINATION; CARDIOVASCULAR DISEASE; CHLORINATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART CATHETERIZATION; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PILOT STUDY; PLASMA; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BOVINE; CHEMISTRY; DONOR; DRUG EFFECTS; HALOGENATION; LUMINESCENCE; METABOLISM; OXIDATION REDUCTION REACTION; PROCEDURES; REPRODUCIBILITY;

AMMONIUM SULFATE; ANIMALS; ANTIOXIDANTS; CATTLE; ENZYME ASSAYS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALOGENATION; HUMANS; LUMINESCENT MEASUREMENTS; LUMINOL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PEROXIDASE; POLYMERS; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; TISSUE DONORS;

EID: 84955446924     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7271     Document Type: Article

References (57)

1. Go, A. S. et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013).
2. Wagner, K.-H. & Brath, H. A global view on the development of non communicable diseases. Prev. Med. 54, S38-S41 (2012).
3. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
4. Naghavi, M. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108, 1772-1778 (2003).
5. McDonnell, B., Hearty, S., Leonard, P. & O'Kennedy, R. Cardiac biomarkers and the case for point-of-care testing. Clin. Biochem. 42, 549-561 (2009).
6. Schultz, J. & Kaminker, K. Myeloperoxidase of the leucocyte of normal human blood. I. Content and localization. Arch. Biochem. Biophys. 96, 465-467 (1962).
7. Klebanoff, S. J., Kettle, A. J., Rosen, H., Winterbourn, C. C. & Nauseef, W. M. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J. Leukoc. Biol. 93, 185-198 (2013).
8. Nicholls, S. J. & Hazen, S. L. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 25, 1102-1111 (2005).
9. Soehnlein, O. Multiple roles for neutrophils in atherosclerosis. Circ. Res. 110, 875-888 (2012).
10. Schindhelm, R. K., van der Zwan, L. P., Teerlink, T. & Scheffer, P. G. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin. Chem. 55, 1462-1470 (2009).
11. Chen, Y., Zhang, F., Dong, L. & Shu, X. Long-term prognostic value of myeloperoxidase on acute coronary syndrome: a meta-analysis. Arch. Med. Res. 42, 368-374 (2011).
12. Sakamoto, W., Fujii, Y., Kanehira, T., Asano, K. & Izumi, H. A novel assay system for myeloperoxidase activity in whole saliva. Clin. Biochem. 41, 584-590 (2008).
13. Franck, T. et al. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. Talanta 80, 723-729 (2009).
14. Gross, S. et al. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat. Med. 15, 455-461 (2009).
15. Sohn, H. Y., Gloe, T., Keller, M., Schoenafinger, K. & Pohl, U. Sensitive superoxide detection in vascular cells by the new chemiluminescence dye L-012. J. Vasc. Res. 36, 456-464 (1999).
16. Daiber, A. et al. Measurement of NAD(P)H oxidase-derived superoxide with the luminol analogue L-012. Free Radic. Biol. Med. 36, 101-111 (2004).
17. Kielland, A. et al. In vivo imaging of reactive oxygen and nitrogen species in inflammation using the luminescent probe L-012. Free Radic. Biol. Med. 47, 760-766 (2009).
18. Frei, B., England, L. & Ames, B. N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc. Natl Acad. Sci. USA 86, 6377-6381 (1989).
19. Chapman, A. L. P. et al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J. Biol. Chem. 288, 6465-6477 (2013).
20. McPherson, R. A. & Pincus, M. R. Henry's Clinical Diagnosis and Management by Laboratory Methods 22nd edn (Saunders, 2011)
21. Kettle, A. J., Gedye, C. A., Hampton, M. B. & Winterbourn, C. C. Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem. J. 308, 559-563 (1995).
22. Curtis, A. S. G. & Forrester, J. V. The competitive effects of serum proteins on cell adhesion. J. Cell Sci. 71, 17-35 (1984).
23. Scharnagl, H. et al. Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography-the LURIC study. Int. J. Cardiol. 174, 96-105 (2014).
24. Nicholls, S. J. et al. Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin. Chem. 57, 1762-1770 (2011).
25. Meuwese, M. C. et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol. 50, 159-165 (2007).
26. Zhang, R. et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286, 2136-2142 (2001).
27. Shih, J. et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin. Chem. 54, 1076-1079 (2008).
28. Scheffer, P. G., van der Zwan, L. P., Schindhelm, R. K., Vermue, H. P. A. & Teerlink, T. Myeloperoxidase concentrations in EDTA-plasma of healthy subjects are discordant with concentrations in heparin-plasma and serum. Clin. Biochem. 42, 1490-1492 (2009).
29. Chang, P.-Y. et al. Development of an ELISA for myeloperoxidase on microplate: normal reference values and effect of temperature on specimen preparation. Clin. Chim. Acta 373, 158-163 (2006).
30. Baldus, S. et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 113, 1871-1878 (2006).
31. Rudolph, T. K. et al. Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. Int. J. Cardiol. 140, 42-47 (2010).
32. Caimi, G. et al. Plasma markers of platelet and polymorphonuclear leukocyte activation in young adults with acute myocardial infarction. Clin. Hemorheol. Microcirc. 32, 67-74 (2005).
33. Eggers, K. M. et al. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin. Biochem. 43, 240-245 (2009).
34. El-Bejjani, D. et al. Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults. HIV Clin. Trials 9, 207-211 (2008).
35. Apple, F. S., Pearce, L. A., Chung, A., Ler, R. & Murakami, M. M. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin. Chem. 53, 874-881 (2007).
36. Michowitz, Y. et al. Usefulness of serum myeloperoxidase in prediction of mortality in patients with severe heart failure. Isr. Med. Assoc. J. 10, 884-888 (2008).
37. Stefanescu, A. et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am. Heart J. 155, 356-360 (2008).
38. Feng, C., Wang, H., Lu, N. & Tu, X. M. Log transformation: application and interpretation in biomedical research. Stat. Med. 32, 230-239 (2013).
39. Do Carmo, R. F. et al. Plasma myeloperoxidase levels correlate with hepatocellular carcinoma in chronic hepatitis C. Hum. Immunol. 73, 1127-1131 (2012).
40. Atukeren, P. et al. Expressions of some vital molecules: glioblastoma multiforme versus normal tissues. Neurol. Res. 32, 492-501 (2010).
41. Liebert, M. A. Protein in gynecological malignancies. Antioxid. Redox Signal. 3, 1139-1146 (2001).
42. Navaneethan, U. et al. Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study. Gastroenterol. Rep. doi:10. 1093/gastro/ gou066 (2014).
43. Hirt, C. et al. Colorectal carcinoma infiltration by myeloperoxidase-expressing neutrophil granulocytes is associated with favorable prognosis. Oncoimmunology 2, e25990 (2013).
44. Droeser, R. A. et al. High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS ONE 8, e64814 (2013).
45. Ky, B. et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J. Am. Coll. Cardiol. 63, 809-816 (2014).
46. Zelzer, S. et al. Myeloperoxidase as serum marker for detection of CMV infections and rejections in patients after liver or heart transplantation. Transpl. Immunol. 20, 121-126 (2009).
47. Koestenbauer, S. et al. Myeloperoxidase and carbonyl proteins: promising markers for non-invasive monitoring of graft rejection after heart transplantation. J. Heart Transplant. 29, 1352-1357 (2010).
48. Hasmann, A. et al. Analysis of myeloperoxidase activity in wound fluids as a marker of infection. Ann. Clin. Biochem. 50, 245-254 (2013).
49. Ciragil, P., Kurutas, E. B. & Miraloglu, M. New markers: urine xanthine oxidase and myeloperoxidase in the early detection of urinary tract infection. Dis. Markers 2014, 269362 (2014).
50. Kothari, N. et al. Increased myeloperoxidase enzyme activity in plasma is an indicator of inflammation and onset of sepsis. J. Crit. Care 26, 435. e1-435. e7 (2011).
51. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676-682 (2012).
52. Horn, B. K. & Sjoberg, R. W. Calculating the reflectance map. Appl. Opt. 18, 1770-1779 (1979).
53. Cox, C. & Ma, G. Asymptotic confidence bands for generalized nonlinear regression models. Biometrics 51, 142-150 (1995).
54. Garden, J. S., Mitchell, D. G. & Mills, W. N. Nonconstant variance regression techniques for calibration-curve-based analysis. Anal. Chem. 52, 2310-2315 (1980).
55. Lavagnini, I. & Magno, F. A statistical overview on univariate calibration, inverse regression, and detection limits: application to gas chromatography/ mass spectrometry technique. Mass Spectrom. Rev. 26, 1-18 (2007).
56. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177-188 (1986).
57. Malle, E., Furtmüller, P. G., Sattler, W. & Obinger, C. Myeloperoxidase: a target for new drug development? Br. J. Pharmacol. 152, 838-854 (2007).